Clinical Variant of Guillain–Barre Syndrome With Prominent Facial Diplegia After AstraZeneca Coronavirus Disease 2019 Vaccine

Badoiu, Anca; Moranne, Olivier; Coudray, Sarah; Ion, Ioana

doi:10.1097/cnd.0000000000000383

Cited by 8 publications

(4 citation statements)

References 7 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Included case series (n = 7) had a mean score of 8.86 ± 0.64 with scores ranging from 8 to 10 [ [25] , [26] , [27] , [28] , [29] , [30] , [31] ]. Meanwhile, the 30 case reports had scores ranging from 5 to 8 with a mean score of 6.57 ± 0.76 [ [4] , [5] , [6] , [7] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] ]. A detailed quality assessment is provided in Supplementary File 3.…”

Section: Methodsmentioning

confidence: 99%

Development of facial palsy following COVID-19 vaccination: A systematic review

Khurshid¹,

Ansari²,

Ahmad³

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Development of facial palsy following COVID-19 vaccination: A systematic review

Khurshid¹,

Ansari²,

Ahmad³

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

“…1 ). All of the included articles are tabulated ( Table 1 ) [ 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 ]. We have excluded one case each from the case series of Bonafacio et al [ 39 ] and Osowicki et al [ 60 ] and four patients from the case series of Garcia-Grimshaw et al [ 69 ] from the final analysis due to the confounding factors implicated in the causation of GBS ( Supplement 3 ).…”

Section: Resultsmentioning

confidence: 99%

Guillain-Barré syndrome associated with SARS-CoV-2 vaccination: how is it different? a systematic review and individual participant data meta-analysis

Reddy,

Murthy,

Osman

et al. 2023

Clin Exp Vaccine Res

View full text Add to dashboard Cite

Purpose An association between Guillain-Barré syndrome (GBS) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination has been reported. We aimed to summarize the clinical features of GBS associated with SARS-CoV-2 vaccination and determine the contrasting features from coronavirus disease-19 (COVID-19) associated GBS and GBS following other causes. Materials and Methods We performed PubMed search for articles published between 1 December 2020 and 27 January 2022 using search terms related to “SARS-CoV-2 vaccination” and “GBS”. Reference searching of the eligible studies was performed. Sociodemographic and vaccination data, clinical and laboratory features, and outcomes were extracted. We compared these findings with post-COVID-19 GBS and International GBS Outcome Study (IGOS) (GBS from other causes) cohorts. Results We included 100 patients in the analysis. Mean age was 56.88 years, and 53% were males. Six-eight received non-replicating virus vector and 30 took messenger RNA (mRNA) vaccines. The median interval between the vaccination and the GBS onset was 11 days. Limb weakness, facial palsy, sensory symptoms, dysautonomia, and respiratory insufficiency were seen in 78.65%, 53.3%, 77.4%, 23.5%, and 25%, respectively. The commonest clinical and electrodiagnostic subtype were sensory-motor variant (68%) and acute inflammatory demyelinating polyneuropathy (61.4%), respectively. And 43.9% had poor outcome (GBS outcome score ≥3). Pain was common with virus vector than mRNA vaccine, and the latter had severe disease at presentation (Hughes grade ≥3). Sensory phenomenon and facial weakness were common in vaccination cohort than post-COVID-19 and IGOS. Conclusion There are distinct differences between GBS associated with SARS-CoV-2 vaccination and GBS due to other causes. Facial weakness and sensory symptoms were commonly seen in the former and outcomes poor.

show abstract

“…However, cranial dominant and classic GBS often initially manifest with bilateral facial weakness and subsequent sensory and motor symptoms in the limbs. Some suspected BFWdp cases following COVID-19 vaccination have been this type of GBS, [ 13 , 14 , 15 , 16 , 17 , 18 , 19 ] and so unequivocal motor weakness or ataxia of the limbs during the disease course negated BFWdp diagnoses. Therefore, we defined BFWdp in this analysis as a bilateral facial weakness with concomitant distal paresthesia without major dysfunction of limbs (i.e., unequivocal weakness or prominent ataxia).…”

Section: Discussionmentioning

confidence: 99%

Bilateral Facial Weakness with Distal Paresthesia Following COVID-19 Vaccination: A Scoping Review for an Atypical Variant of Guillain–Barré Syndrome

Kim

Yoon

et al. 2022

Brain Sciences

View full text Add to dashboard Cite

Background and Purpose: Recent population-based studies from the US and UK have identified an increase in the occurrence of Guillain–Barré syndrome (GBS) following coronavirus disease 2019 (COVID-19) vaccination. However, the localized variant of GBS might be underestimated due to its rarity and atypical features. We aimed to identify and characterize bilateral facial weakness with distal paresthesia (BFWdp) as a GBS variant following COVID-19 vaccination. Materials and Methods: Relevant studies published during the COVID-19 pandemic were searched and identified in the MEDLINE, Embase, and other databases. Results: This review found that 18 BFWdp cases presented characteristics similar to previous BFWdp cases as defined in the literature: male dominance, frequent albuminocytological dissociation, and acute inflammatory demyelinating neuropathy pattern. In contrast, facial nerve enhancement on brain MRI and antiganglioside antibody positivity were often observed in BFWdp following COVID-19 vaccination. Conclusions: The mechanism of BFWdp following COVID-19 vaccination appears to be somewhat different from that of sporadic BFWdp. Neurological syndromes with rare incidence and difficulty in diagnosis should be considered adverse events of COVID-19 vaccination.

show abstract

Clinical Variant of Guillain–Barre Syndrome With Prominent Facial Diplegia After AstraZeneca Coronavirus Disease 2019 Vaccine

Cited by 8 publications

References 7 publications

Development of facial palsy following COVID-19 vaccination: A systematic review

Development of facial palsy following COVID-19 vaccination: A systematic review

Guillain-Barré syndrome associated with SARS-CoV-2 vaccination: how is it different? a systematic review and individual participant data meta-analysis

Bilateral Facial Weakness with Distal Paresthesia Following COVID-19 Vaccination: A Scoping Review for an Atypical Variant of Guillain–Barré Syndrome

Contact Info

Product

Resources

About